BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3488023)

  • 1. [Development of cancer immunotherapy by a combination of biological response modifiers on the basis of their mechanism of action].
    Toge T; Tomota S; Aratani K; Kameda A; Yamada H; Yanagawa E; Hattori T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1258-63. PubMed ID: 3488023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
    Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
    Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interleukin 2].
    Taguchi T; Kimoto Y
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1203-7. PubMed ID: 3495239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
    J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological Response Modifiers Programme and cancer chemotherapy.
    Oldham RK
    Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current possibilities in immunotherapy of cancer].
    von Fliedner V
    Schweiz Med Wochenschr; 1987 Feb; 117(7):243-8. PubMed ID: 3551061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
    Kimoto Y; Taguchi T
    Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunological effects of locoregional immunochemotherapy for liver metastases of gastric cancer].
    Sugiyama Y; Kato M; Takao H; Kida H; Kunieda K; Umemoto T; Miya K; Azuma S; Furuta T; Saji S
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1461-4. PubMed ID: 8373205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Locoregional therapy for liver metastases of colorectal cancer].
    Sugiyama Y; Saji S; Miya K; Fukada D; Umemoto T; Kunieda K; Takao H; Kato M; Kawai M
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1433-6. PubMed ID: 8854772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
    Wang C; Chai L; Zhu G
    Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):27-9. PubMed ID: 7656782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
    Ishida N; Saito M; Nanjo M
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [BRM in the treatment of cancer].
    Takaku F
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1597-602. PubMed ID: 2454612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experimental studies on the amplification of anti-tumor effects using bacterial DNA-treated cancer cells, immunoactivators and interferon].
    Kitasato M
    Nihon Gan Chiryo Gakkai Shi; 1985 Jul; 20(6):1107-16. PubMed ID: 3934297
    [No Abstract]   [Full Text] [Related]  

  • 19. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer.
    Yu B; Kusmartsev S; Cheng F; Paolini M; Nefedova Y; Sotomayor E; Gabrilovich D
    Clin Cancer Res; 2003 Jan; 9(1):285-94. PubMed ID: 12538481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive immunotherapy of cancer: accomplishments and prospects.
    Rosenberg SA
    Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.